Randomization split
Arm logic
One enrolment line, three treatment arms. What the config team does to that split after first patient in is the number that decides the maintenance cost.
Independent clinical trial technology resource
Cambridge, Massachusetts
Comparing RTSM platforms without the vendor pitch
Every live reading, one panel, before the vial moves. We read the RTSM/IRT market workflow by workflow, study by study — for US sponsors and clinical operations teams who have to make the call.
Where to start
An independent clinical technology resource, not a vendor page
Sudova Agent is an independent clinical trial technology resource. We read the RTSM/IRT market the way a clinical operations lead has to: workflow by workflow, study by study. If you are picking a randomization and trial supply platform for a US trial, or deciding whether a broad eClinical suite earns its place over a focused provider, start here and follow the page that matches your decision.
Nothing on this site is paid placement, and no platform is presented as the right answer without saying which study type it fits. That constraint is the point — it is also why we will never tell you a platform is right for every trial.
Temperature window
Excursion path
Where the depot brackets sit, and what an out-of-window shipment does to the kit — that is the supply half of RTSM, not a sidebar.
Connected suite
Six bays, one contract
RTSM, EDC, CTMS, eTMF, eCOA and ePRO as one stack — the bundling case is real, and so is the switching cost it hides.
A trial kit room at 8 in the morning, before the vial moves.
The capability bays
What RTSM actually does on a study
Randomization and trial supply management covers more ground than the name suggests. It handles treatment assignment at the point of enrollment, then keeps the depot honest: kit allocation, resupply triggers, expiry control, temperature excursions, and unblinding rules for the people who need them. IWRS and IRT describe the same class of system, and RTSM is the term much of the industry settled on.
Assignment and scheduling
Randomisation and IWRS scheduling
Treatment assignment at enrollment, then the schedule that keeps sites supplied: stratification factors, dynamic allocation, cohort triggers and the pathway a site follows for an unblinding request. The workflow detail here is what separates a focused IRT provider from a suite module — you should read both on the same page before comparing.
What to check first
Whether the randomization engine accepts a changed stratification factor without invalidating runs already completed.
What usually breaks
A schedule built as a fixed template, then amended — that is where maintenance cost quietly grows.
Supply chain
Trial supply and depot visibility
Depots, shipments and kit releases are one continuous route: allocation strategy, expiry control, resupply triggers, and what happens to a shipment that leaves its temperature window before it reaches the site.
What to check first
Real-time supply visibility across depots, not a report you pull the following week.
Where the pain lands
A changed arm count that leaves kits on the shelf — the obsolescence question belongs in the amendment discussion, not after it.
Participant-facing
eConsent, eCOA and ePRO
The participant side is now a product category of its own. eConsent handles the join, eCOA and ePRO capture what participants and clinicians report between visits, and a single login for consent, questionnaires and visit reminders beats three portals and a phone call.
What to check first
Language coverage in the participant-facing tools, and whether the handoff from consent into randomization runs without duplicate entry.
The trade-off
A participant-facing module ties teams further into that vendor's stack. Weigh the experience against the switching cost before it becomes a checkbox.
The first fork
Standalone RTSM or a full eClinical suite
A focused RTSM vendor often ships deeper supply logic and faster configuration for a study that lives or dies by its randomization and depot. A broad suite can put RTSM beside EDC, CTMS, eCOA, eConsent and eTMF under one contract and one integration layer. Neither wins on principle. The question is which fragmentation you would rather live with.
Reading
Scope: whole platform
RTSM / IRT platforms
Focused providers-
YPrime
One platform covering consent, randomization, trial supply and outcome data — sold as a way to stop juggling vendors.
-
Suvoda
Evaluated in the market as an IRT-focused platform, alongside the broader suite vendors in current US trial descriptions.
-
Signant
Appears in current comparisons for US trials with a scope that leans toward the clinical outcome and RTSM side.
-
Medrio
Spans CTMS through RTSM — the November 2026 CTMS launch is a useful example of the consolidation pattern.
Broad eClinical suites
One contract, one layer-
IQVIA
Evaluated by sponsors that want scale across operations and data, not a single-purpose IRT tool.
-
Medidata
myMedidata is the clearest current example of a participant-facing layer sitting alongside EDC and RTSM in suite conversations.
-
Medrio
Describes CTMS, EDC, eCOA/ePRO, eConsent, eTMF and RTSM as one connected platform — whether that reduces workflow friction is a question you answer.
The deciding factor is not the portfolio size: it is how each option would walk through a mid-study amendment comparable to one you have already run.
Where claims meet reality
Where mid-study changes get decided
Boundary case
A change that flows through configuration, or a rebuild
Adding an arm, changing a stratification factor, or moving a country's depot mid-study is the point where platform claims turn into work. Ask any vendor how a treatment-arm addition was handled on a comparable study, and ask who does the work. That last question — in-house service team or a partner routed on the back end — is where the answer usually changes.
No comparable published
Where a vendor publishes no comparable amendment, we say so and label the gap. Our coverage does not pretend to have an answer for a claim only that vendor's own material carries — those stay labelled as vendor-stated.
How a buyer should test it
This is usually where solo RTSM vendors argue their case: a small, dedicated team often turns an amendment faster than a large portfolio queue. It is also where broad suites return the favor, because one integration layer means fewer conversations when the change crosses EDC, CTMS and supply at once. Neither answer is universal — bring the specifics of your last three amendments.
The first week of an evaluation, in the room where the reading happens.
The questions US sponsors actually ask
What decides the platform in month eighteen
Scoping the change surface
Pull three recent studies of comparable complexity, list every change made after first patient in, and ask each vendor to walk through how they would handle those changes. Then check integration points with your EDC and CTMS, confirm the validation documentation your quality group will need, and find out who owns support in your time zone. Do this before pricing conversations — a lower quote with a slower amendment path is not a lower cost.
Participant-facing tools, named plainly
Medidata's myMedidata is the clearest current example: a participant-facing layer that sits alongside EDC and RTSM in suite conversations. If your teams already run Medidata, the integration case is straightforward. If they do not, weigh the participant experience against the switching cost before it becomes a checkbox on a feature matrix.
US sponsors running global trials
A platform that works for a Boston site may strain in a country with a different depot structure, language requirement, or local reporting format. Language coverage in the participant-facing tools, local supply routes, and whether support follows the sun or follows the vendor's headquarters — those are the questions to settle early. They tend to decide which platform a study team actually enjoys using at month eighteen.
Complex, multi-arm, or adaptive studies
Dynamic randomization and stratification logic, real-time supply visibility across depots, and a proven path for protocol amendments after first patient in. Adaptive designs add another requirement: the randomization engine has to accept design changes without invalidating what already ran. Ask for the amendment history, then check that the supply plan can absorb a changed arm count without kit obsolescence.
How the pages here are organized
The platform comparison puts RTSM and adjacent vendors side by side on workflow coverage, service model, and mid-study change handling. The capability guides explain what each system does, so a randomization feature and an eCOA feature are not compared as if they were the same kind of thing. Study complexity helps you decide which platform class your design actually needs. The evaluation method page shows how we research and where our limitations are.
Reference
The questions we get by email
Short answers to the questions sponsors and clinical operations leads send us when they are already mid-evaluation.
Send us a correctionWhat is the difference between RTSM and IRT?
They describe the same class of system. IRT (interactive response technology) and IWRS (interactive web response system) are older and more generic labels. RTSM (randomization and trial supply management) names the two jobs the system actually performs, which is why much of the industry now uses it. Some vendors still write IRT on pages aimed at complex studies, and the underlying capability is the same.
How do sponsors compare standalone RTSM vendors with broader eClinical suites?
Start with what the study needs, not what the portfolio offers. A focused RTSM vendor tends to be stronger on supply logic and fast configuration. A broad suite wins on integration with EDC, CTMS, eConsent and eCOA under one contract. Then test the deciding factor directly: ask each option to walk through a mid-study amendment comparable to one you have already run.
How important is integration with EDC, CTMS and eConsent?
It matters most where data or participants cross system boundaries. Randomization must reconcile with the clinical database, CTMS must see enrollment and site activity, and eConsent must hand a consented participant into the treatment workflow without duplicate entry. If your EDC and RTSM come from the same vendor the integration question is smaller; if they do not, ask for the interface specification, not a reassurance.
Which vendors are most established in the US clinical trial technology market?
IQVIA, Medidata, Medrio, Suvoda, Signant and YPrime all appear in current platform descriptions for US trials, with different scopes. IQVIA and Medidata are broad suite vendors. YPrime and Suvoda are evaluated as IRT-focused platforms. Medrio spans CTMS through RTSM. Establishment is worth knowing, but it does not answer whether a platform fits your design.
What features matter most in complex, multi-arm or adaptive studies?
Dynamic randomization and stratification logic, real-time supply visibility across depots, and a proven path for protocol amendments after first patient in. Adaptive designs add another requirement: the randomization engine has to accept design changes without invalidating what already ran. Ask for the amendment history, then check that the supply plan can absorb a changed arm count without kit obsolescence.
Where independent resources stop and vendors start
We are not the vendor. That is the point.
Sudova Agent is not a vendor and does not sell RTSM. We do not take payment for placement in comparisons, and we do not present a platform as the right answer without saying which study type it fits. Where our coverage has gaps, we say so. Where a vendor's own materials are the only source for a claim, we label it as vendor-stated. It is also why this site will never tell you a platform is right for every trial.
Start with whichever fork is open in front of you
- Platform comparison RTSM and adjacent vendors side by side on workflow coverage, service model and mid-study change handling.
- Capability guides What each system does, so a randomization feature and an eCOA feature are not compared as the same kind of thing.
- Study complexity Which platform class your design actually needs — arms, stratifications, amendments.
- Evaluation method How we research and where our limitations are.
- Send us a correction If our reading of a platform is out of date, tell us and we will revisit the comparison.